We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Ocugen's Q2 Earnings Miss Estimates as R&D Costs Rise, Stock Falls
Read MoreHide Full Article
Key Takeaways
OCGN reported a wider Q2 loss as higher R&D costs offset a modest revenue beat from collaboration income.
Ocugen raised cash, retired higher-interest debt, and extended its cash runway into 2028.
OCGN advanced key gene therapy programs, with multiple late-stage data readouts and BLA filings planned.
Ocugen (OCGN - Free Report) reported a second-quarter 2026 loss of 7 cents per share, which was wider than the Zacks Consensus Estimate as well as the year-ago loss of 5 cents. Higher research and development spending weighed on results.
Revenues rose 8.4% year over year to $1.5 million and slightly beat the Zacks Consensus Estimate of $1.4 million. The company’s top line currently comprises only collaboration revenues.
OCGN’s Costs Climb as Pipeline Spending Advances
Total operating expenses increased 18.2% year over year to $17.9 million. Research and development expenses rose 27.2% to $10.7 million, while general and administrative expenses increased 7.0% to $7.2 million.
Cash, cash equivalents and restricted cash totaled $100.4 million as of June 30, 2026, up from $32.2 million as of March 31. The increase followed the closing of $130.0 million of 6.75% convertible senior notes due 2034, which generated about $112.5 million in net proceeds.
Ocugen used about $32.7 million of those proceeds to fully retire its Avenue Capital loan and eliminate 12.25% interest-rate debt. Management expects the financing to extend the cash runway into 2028, supporting the company’s late-stage clinical programs and planned regulatory submissions.
Ocugen’s shares declined 3% on Wednesday after the results were announced. Year to date, shares of OCGN have declined 8.2% compared with the industry’s 3.5% decline.
Image Source: Zacks Investment Research
OCGN’s Pipeline Progress & Clinical Updates
Ocugen is advancing its ophthalmology gene therapy pipeline, targeting three biologics license application (BLA) submissions by 2028. The first half of 2027 is expected to be catalyst-rich, with late-stage top-line data anticipated for OCU400 and OCU410ST.
Enrollment has been completed in a phase III liMeliGhT study on lead modifier gene therapy candidate, OCU400, to treat Retinitis pigmentosa, or RP, a rare genetic disorder that can lead to vision loss and blindness. Top-line data from the phase III study is expected in the first quarter of 2027. Management said the FDA feedback keeps the rolling BLA pathway tied to the top-line data, with completion of the filing targeted for the second quarter of 2027 and potential approval in the fourth quarter as a treatment option for early- to late-stage RP.
OCU410ST is being developed as a one-time gene therapy for the treatment of Stargardt disease, a rare inherited retinal disorder. In April 2026, the company completed enrollment and dosing in the phase II/III GARDian3 pivotal confirmatory study on OCU410ST for Stargardt disease. Management expects an interim outcome decision for the first 50% of subjects at eight months in the third quarter of 2026. Top-line data are anticipated in the second quarter of 2027, with a BLA submission planned for mid-2027.
The FDA cleared the phase III ArMaDa3 registrational study of Ocugen’s another important candidate, OCU410, for geographic atrophy, an advanced stage of dry age-related macular degeneration. Ocugen plans to initiate the global phase III study by September. The program is supported by positive 12-month phase II data showing a statistically significant 31% reduction in geographic atrophy lesion growth at the optimal dose in the target lesion-size population. BLA and Marketing Authorization Application filings are targeted for 2028.
Over the past 60 days, estimates for Repligen’s 2026 earnings per share have risen from $1.99 to $2.06, while estimates for 2027 have increased from $2.57 to $2.62 during the same time. RGEN shares have declined 2.7% year to date.
Repligen’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 16.80%.
Over the past 60 days, estimates for Harmony Biosciences’ 2026 earnings per share have risen from $3.20 to $3.33. Over the same period, EPS estimates for 2027 have surged from $3.64 to $3.92. HRMY shares are up 3.6% year to date.
Harmony Biosciences’ earnings missed estimates in three of the trailing four quarters, while beating in just one, with the average negative surprise being 13.97%.
Over the past 60 days, estimates for Liquidia’s 2026 earnings per share have risen from $2.97 to $3.02, while estimates for 2027 have increased from $4.81 to $5.31 during the same time. LQDA shares have surged 159.3% year to date.
Liquidia’s earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with the average surprise being 54.40%.
View the Zacks #1 Rank List
Image: Bigstock
Ocugen's Q2 Earnings Miss Estimates as R&D Costs Rise, Stock Falls
Key Takeaways
Ocugen (OCGN - Free Report) reported a second-quarter 2026 loss of 7 cents per share, which was wider than the Zacks Consensus Estimate as well as the year-ago loss of 5 cents. Higher research and development spending weighed on results.
Revenues rose 8.4% year over year to $1.5 million and slightly beat the Zacks Consensus Estimate of $1.4 million. The company’s top line currently comprises only collaboration revenues.
OCGN’s Costs Climb as Pipeline Spending Advances
Total operating expenses increased 18.2% year over year to $17.9 million. Research and development expenses rose 27.2% to $10.7 million, while general and administrative expenses increased 7.0% to $7.2 million.
Cash, cash equivalents and restricted cash totaled $100.4 million as of June 30, 2026, up from $32.2 million as of March 31. The increase followed the closing of $130.0 million of 6.75% convertible senior notes due 2034, which generated about $112.5 million in net proceeds.
Ocugen used about $32.7 million of those proceeds to fully retire its Avenue Capital loan and eliminate 12.25% interest-rate debt. Management expects the financing to extend the cash runway into 2028, supporting the company’s late-stage clinical programs and planned regulatory submissions.
Ocugen’s shares declined 3% on Wednesday after the results were announced. Year to date, shares of OCGN have declined 8.2% compared with the industry’s 3.5% decline.
Image Source: Zacks Investment Research
OCGN’s Pipeline Progress & Clinical Updates
Ocugen is advancing its ophthalmology gene therapy pipeline, targeting three biologics license application (BLA) submissions by 2028. The first half of 2027 is expected to be catalyst-rich, with late-stage top-line data anticipated for OCU400 and OCU410ST.
Enrollment has been completed in a phase III liMeliGhT study on lead modifier gene therapy candidate, OCU400, to treat Retinitis pigmentosa, or RP, a rare genetic disorder that can lead to vision loss and blindness. Top-line data from the phase III study is expected in the first quarter of 2027. Management said the FDA feedback keeps the rolling BLA pathway tied to the top-line data, with completion of the filing targeted for the second quarter of 2027 and potential approval in the fourth quarter as a treatment option for early- to late-stage RP.
OCU410ST is being developed as a one-time gene therapy for the treatment of Stargardt disease, a rare inherited retinal disorder. In April 2026, the company completed enrollment and dosing in the phase II/III GARDian3 pivotal confirmatory study on OCU410ST for Stargardt disease. Management expects an interim outcome decision for the first 50% of subjects at eight months in the third quarter of 2026. Top-line data are anticipated in the second quarter of 2027, with a BLA submission planned for mid-2027.
The FDA cleared the phase III ArMaDa3 registrational study of Ocugen’s another important candidate, OCU410, for geographic atrophy, an advanced stage of dry age-related macular degeneration. Ocugen plans to initiate the global phase III study by September. The program is supported by positive 12-month phase II data showing a statistically significant 31% reduction in geographic atrophy lesion growth at the optimal dose in the target lesion-size population. BLA and Marketing Authorization Application filings are targeted for 2028.
OCGN's Zacks Rank & Stocks to Consider
Ocugen currently carries a Zacks Rank #3 (Hold).
Ocugen, Inc. Price and Consensus
Ocugen, Inc. price-consensus-chart | Ocugen, Inc. Quote
Some better-ranked stocks in the biotech sector are Repligen (RGEN - Free Report) , Harmony Biosciences (HRMY - Free Report) and Liquidia Corporation (LQDA - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Repligen’s 2026 earnings per share have risen from $1.99 to $2.06, while estimates for 2027 have increased from $2.57 to $2.62 during the same time. RGEN shares have declined 2.7% year to date.
Repligen’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 16.80%.
Over the past 60 days, estimates for Harmony Biosciences’ 2026 earnings per share have risen from $3.20 to $3.33. Over the same period, EPS estimates for 2027 have surged from $3.64 to $3.92. HRMY shares are up 3.6% year to date.
Harmony Biosciences’ earnings missed estimates in three of the trailing four quarters, while beating in just one, with the average negative surprise being 13.97%.
Over the past 60 days, estimates for Liquidia’s 2026 earnings per share have risen from $2.97 to $3.02, while estimates for 2027 have increased from $4.81 to $5.31 during the same time. LQDA shares have surged 159.3% year to date.
Liquidia’s earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with the average surprise being 54.40%.